Understanding the Expanding Role of Antibody-Drug Conjugates in Bladder Cancer
Elizabeth R. Plimack, MD, MS, FASCO
Lillibeth Velasco, MSN, RN
Reviewing the Latest Bladder Cancer Practice Guidelines
Patient Perspectives on Bladder Cancer
Establishing D-VRd Efficacy for Transplant-Ineligible Multiple Myeloma
Understanding Anemia in Myelofibrosis: Multifactorial Origins and Management Strategies
Charles Turck, PharmD, BCPS, BCCCP
Prithviraj Bose, MD
A Patient-Centered Approach to Managing Anemia in Myelofibrosis
Brian P. McDonough, MD, FAAFP
John Mascarenhas, MD
Lucia Masarova, MD
Managing Anemia in Myelofibrosis: A Multidisciplinary Approach
Douglas Tremblay, MD
Marina Kremyanskaya, MD
Exercise in Multiple Myeloma: Balancing Benefits and Safety
Jens Hillengass, MD, PhD
Molecular Profiling for HER2+ Advanced Solid Tumors
Eric Van Cutsem, MD, PhD
David SP Tan, MBBS, PhD, PRCP
James Chih-Hsin Yang, MD, PhD
Kathleen Moore, MD, MS, FASCO
Managing Early Esophageal and Gastric Cancers: ASGE Recommendations on ESD and EMR
Peter Buch, MD, FACG, AGAF, FACP
Vivek Kaul, MD
Diagnosis and Management of Metastatic PDAC
Efrat Dotan, MD
Shubham Pant, MD, MBBS
Predictive Models for CAR T-Cell Therapy: Personalizing R/R LBCL Care
Matthew Matasar, MD
Sacituzumab Govitecan for mTNBC: A Review of Real-World Efficacy and Safety Data
Paolo Tarantino, MD
Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety Protocols
Tara Graff, DO, MS
Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings
Jacob Sands, MD
Julia Rotow, MD
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers
Laura Alder, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.